The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome

Journal of Endocrinological Investigation

Volumn 39, Issue 8, 2016, Pages 917-922

  Hosseinzadeh Attar, M J ^a   Golpaie, A ^b   Foroughi, M ^b   Hosseinpanah, F ^c   Zahediasl, S ^d   Azizi, F ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CRP; IL 6; Metabolic syndrome; Visceral adiposity; Visfatin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; AUTACOID;

ABDOMINAL OBESITY; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION COEFFICIENT; HUMAN; INFLAMMATION; MALE; METABOLIC ACIDOSIS; OBESITY; PROTEIN BLOOD LEVEL; STUDENT T TEST; VISCERAL ADIPOSITY; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED;

BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY;

EID: 84978472275     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-016-0457-1     Document Type: Article

References (52)

1. Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The national cholesterol education program-adult treatment panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1):8
2. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366(9491):1059
3. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. Vascular 7:8
4. Maury E, Brichard S (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16
5. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al (2000) Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2):179–184
6. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al (2004) Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 53(8):2087–2094
7. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595
8. Koh KK, Han SH, Quon MJ (2005) Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46(11):1978–1985
9. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793
10. Juge-Aubry CE, Henrichot E, Meier CA (2005) Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 19(4):547–566
11. Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47(3):403
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557–1565
13. Devaraj S, Singh U, Jialal I (2009) Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 20(3):182
14. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978
15. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F (1999) Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 99(16):2219–2222
16. Ognjanovic S, Bao S, Yamamoto S, Garibay-Tupas J, Samal B, Bryant-Greenwood G (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26(2):107–117
17. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289(4):E586–E590
18. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185(3):R1
19. Ahima RS (2006) Adipose tissue as an endocrine organ. Obesity 14:242S–249S
20. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426
21. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165
22. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578
23. Sandeep S, Velmurugan K, Deepa R, Mohan V (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56(4):565–570
24. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al (2005) Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes 54(10):2911
25. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M et al (2007) Serum concentration of visfatin in obese women. Metabolism 56(8):1131–1134
26. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L et al (2008) Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 79(3):412–418
27. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H et al (2009) Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 139(1–2):22–27
28. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al (2007) Nampt/PBEF/visfatin regulates insulin secretion in [beta] cells as a systemic NAD biosynthetic enzyme. Cell Metab 6(5):363–375
29. Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF (2010) Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2(1):1–6
30. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M et al (2002) Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 47(6):408–426
31. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M et al (2009) Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 10(5):19166627
32. Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, Lee KW et al (2008) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 79(1):108–111
33. Kim JH, Kim SH, Im JA, Lee DC (2010) The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 67(1):67–71
34. Zhong M, Tan H, Gong H, Wang S, Zhang Y, Zhang W (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 69(6):878–884
35. Filippatos T, Derdemezis C, Gazi I, Lagos K, Kiortsis D, Tselepis A et al (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38(1):71–72
36. Lin CC, Lai MM, Li TC, Li CI, Liu CS, Chen CC et al (2009) Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 85(1):24–29
37. Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B (2011) Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome. Kardiol Polska 69(8):802
38. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT et al (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56(9):1216–1220
39. Wen Y, Wang H, Wu J, Lu H, Hu XF, Cianflone K (2006) Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119(20):1701
40. MacLaren R, Cui W, Cianflone K (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 9(4):490–497
41. Nüsken KD, Niisken E, Petrasch M, Rauh M, Dötsch J (2007) Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 382(1–2):154–156
42. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92(12):4783–4791
43. Mohamed-Ali V, Pinkney J, Coppack S (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes 22:1145–1158
44. Pickup J, Mattock M, Chusney G, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11):1286–1292
45. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148(2):209–214
46. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D et al (2006) C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 71(1):92–100
47. Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144(6):2195–2200
48. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome x: contribution of adipocytokines· adipocyte-derived bioactive substances. Ann N Y Acad Sci 892(1):146–154
49. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA et al (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18(14):1657–1669
50. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7
51. Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24(3):278–301
52. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes. Arterioscler Thromb Vasc Biol 25(6):1231–1236